-+ 0.00%
-+ 0.00%
-+ 0.00%

Bolt Biotherapeutics shareholders elect Quinn, Dupont to board class II seats

PUBT·06/11/2026 20:06:56
Listen to the news
Bolt Biotherapeutics shareholders elect Quinn, Dupont to board class II seats
  • Bolt Biotherapeutics held its annual stockholder meeting on June 10, 2026.
  • Stockholders backed the board’s slate of Class II director nominees for terms running to the 2029 annual meeting.
  • PricewaterhouseCoopers was ratified as independent registered public accounting firm for the year ending Dec. 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-267487), on June 11, 2026, and is solely responsible for the information contained therein.